A comparative pharmacokinetic study of diazepam nasal spray in in Chinese subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jun 2023 According to a China Medical System media release, the company announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray received approval from the National Medical Products Administration of China (NMPA).
05 Jul 2021 According to a China Medical System media release, New Drug Application of Diazepam Nasal Spray (the "Product") has been accepted by the National Medical Products Administration of the People's Republic of China.
21 Oct 2020 According to a China Medical System media release, the clinical trial notice issued by China NMPA, the company has to conduct this bridging trial to support its registration of the drug in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com